New Partners Initiative Translational HIV Research for Innovative Vaccines Ecosystem (NPI THRIVE)
ID: 357803Type: Posted
Overview

Buyer

Agency for International Development (USAID)

Award Range

$99M - $99M

Eligible Applicants

Nonprofits Without 501(c)(3) Status

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357803
Timeline
    Description

    The United States Agency for International Development (USAID) is inviting applications for the New Partners Initiative Translational HIV Research for Innovative Vaccines Ecosystem (NPI THRIVE), aimed at accelerating the development of a safe and effective HIV vaccine through collaborative research led by African scientists and institutions. This funding opportunity includes at least two cooperative agreements, with a total funding ceiling of $98.5 million over five years, structured around two main objectives: enhancing African-led clinical research and advancing promising immunogens towards first-in-human studies. The program emphasizes innovative, locally-led approaches and is open to a wide range of eligible applicants, including nonprofits without 501(c)(3) status, with a focus on projects predominantly within African countries to leverage local capabilities in addressing global HIV vaccine research challenges. Interested parties must submit a concept paper by January 28, 2025, and can contact Elton Fortson at npithrive@usaid.gov for further information regarding the application process.

    Point(s) of Contact
    npithrive@usaid.gov
    Files
    Title
    Posted
    7200AA25RFA00001-.pdf
    USAID has issued a Notice of Funding Opportunity (NOFO) for the New Partners Initiative Translational HIV Research for Innovative Vaccines Ecosystem (NPI THRIVE), aiming to develop a safe and effective HIV vaccine through collaborative research led by African scientists. The funding opportunity includes at least two cooperative agreements totaling up to $98.5 million over five years, structured around two main objectives: fostering African-led clinical research and advancing promising immunogens towards first-in-human studies. Eligible applicants range from local entities to organizations that have not previously received USAID funding. The application process involves three phases: submitting a concept paper, co-creating proposals with USAID, and finally submitting a full application. The emphasis is on innovative, locally-led approaches, aligning with the principles of equity, local leadership, and effective resource utilization. The program specifically aims for projects predominantly within African countries, leveraging local capabilities to influence global HIV vaccine research and support sustainable development in high-burden regions. An extensive framework outlines performance indicators, intellectual property rights, and the expected timeline for the project, stressing collaboration and community engagement throughout the implementation process to ensure effective outcomes.
    Annex.bin
    Similar Opportunities
    Accelerating HIV Vaccine Research and Development in Low- and Middle-Income Countries (LMIC)
    Active
    Agency for International Development
    The United States Agency for International Development (USAID) is seeking expert input through a Request for Information (RFI) aimed at accelerating HIV vaccine research and development in low- and middle-income countries (LMICs). This initiative is designed to gather recommendations on opportunities, challenges, and gaps in HIV vaccine R&D, particularly focusing on collaborative ecosystems, efficient manufacturing, and community engagement. The RFI underscores USAID's commitment to enhancing partnerships and locally-led development in regions significantly impacted by HIV, including outreach to historically black colleges and universities (HBCUs) and minority-serving institutions (MSIs). Interested parties must submit their responses electronically by May 24, 2024, at 5:00 PM EDT, adhering to specific formatting guidelines, and can direct inquiries to Simone Cho at scho@usaid.gov.
    Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD), aimed at advancing HIV-1 vaccine candidates from preclinical studies to clinical trial readiness. This program supports a range of activities including immunogenicity studies, manufacturing processes, and regulatory compliance, with a focus on innovative vaccine technologies that can elicit broadly neutralizing antibodies. The funding opportunity is significant in addressing ongoing health challenges related to the HIV/AIDS epidemic, with an award ceiling of $3 million and applications due by March 14, 2025. Interested applicants can find more information and submission details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    New Partnerships Initiative (NPI) – Global Health
    Active
    Agency for International Development
    The U.S. Agency for International Development (USAID) is offering a funding opportunity through the New Partnerships Initiative (NPI) Global Health Annual Program Statement (APS) aimed at engaging new and underutilized partners to enhance health sector outcomes. This initiative focuses on supporting community-based interventions, particularly in response to COVID-19, by inviting organizations to submit Concept Papers that align with national health policies and emphasize local partnerships. The funding opportunity is significant, with a total ceiling of up to $100 million available for multiple awards, and the closing date for submissions is September 30, 2030. Interested applicants can reach out to USAID at ghnpiaps@usaid.gov for further information and guidance on the application process.
    Microbicides Research, Development, and Introduction
    Active
    Agency for International Development
    The U.S. Agency for International Development (USAID) is offering a federal grant opportunity titled "Microbicides Research, Development, and Introduction" aimed at advancing research and innovative activities related to microbicides for HIV prevention. This initiative seeks to support clinical trials and other activities that contribute to the Global Health Initiative's principles, particularly focusing on a woman- and girl-centered approach and strengthening health systems. The funding amounts range from $100,000 to $2,250,000, with no cost-sharing or matching requirements, and interested applicants can contact Kathleen Bumpass at kbumpass@usaid.gov for further information. The closing date for applications is to be determined.
    HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "HIV Vaccine Research and Design (HIVRAD) Program," aimed at advancing research for an effective prophylactic vaccine against HIV/AIDS. This grant encourages multi-disciplinary projects that address significant scientific questions in vaccine discovery, including preclinical evaluations in non-human primate models, while explicitly prohibiting clinical trials. The NIH plans to fund 1-2 awards totaling approximately $5 million for fiscal year 2025, with applications due by March 13, 2024, and an open submission date starting February 13, 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application guidelines available at https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html.
    Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models," aimed at supporting preclinical research on HIV/AIDS conducted by early-stage investigators with at least two years of postdoctoral experience. This funding initiative encourages innovative research approaches utilizing NHP models to develop next-generation therapies and strategies for HIV cure, aligning with the NIH Strategic Plan priorities for HIV research. Eligible applicants can request up to $200,000 in direct costs annually, with a total budget cap of $400,000 over two years, and must adhere to specific application procedures. The application deadline is September 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Comprehensive District-Based Support for Better HIV/TB Patient Outcomes
    Active
    South Africa USAID-Pretoria
    The United States Agency for International Development (USAID) Mission to Southern Africa is seeking applications for a five-year cooperative agreement aimed at implementing comprehensive district-based HIV-related services to improve patient outcomes. This initiative is part of a broader effort to enhance health services in the region, specifically targeting better management and support for HIV and tuberculosis patients. With an estimated total program funding of $75 million, the agency anticipates awarding four grants, with individual awards ranging from $1 to $20 million. Interested organizations are encouraged to participate in a pre-application conference scheduled for May 14, 2012, in Johannesburg, South Africa, to clarify the application process and technical objectives; registration is required by January 23, 2012. For further inquiries, applicants can contact Beatrice Lumande at Applications4@usaid.gov or by phone at +27 12 452 2377.